Evidence map›Paper›PMID 39987535›Full record

ReviewMedical oncology (Northwood, London, England)2025

Metal nanoparticles as a promising therapeutic approach for prostate cancer diagnosis and therapy: a comprehensive review.

Mohamed J Saadh, Wajida Ataallah Khidr, Karar H Alfarttoosi, Ashok Kumar Bishoyi, Subbulakshmi Ganesan, Aman Shankhyan, S Gayathri, Jasur Rizaev, Waam Mohammed Taher, Mariem Alwan and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Selenium-Containing Compounds in Breast Cancer Therapy.Biological trace element research · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mohamed J SaadhFaculty of Pharmacy, Middle East University, Amman, 11831, Jordan.
Wajida Ataallah KhidrDepartment of Medical Laboratory Technics, College of Health and Medical Technology, Alnoor University, Mosul, Iraq. wajida.ataallah@alnoor.edu.iq.
Karar H AlfarttoosiCollege of Pharmacy, Ahl Al Bayt University, Karbala, Iraq.
Ashok Kumar BishoyiDepartment of Microbiology, Marwadi University Research Center, Faculty of Science, Marwadi University, Rajkot, Gujarat, 360003, India.
Subbulakshmi GanesanDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Aman ShankhyanCentre for Research Impact and Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab, 140401, India.
S GayathriDepartment of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Jasur RizaevDepartment of Public Health and Healthcare Management, Rector, Samarkand State Medical University, 18, Amir Temur Street, Samarkand, Uzbekistan.
Waam Mohammed TaherCollege of Nursing, National University of Science and Technology, Nasiriyah, Dhi Qar, Iraq.
Mariem AlwanPharmacy College, Al-Farahidi University, Baghdad, Iraq.
Mahmood Jasem JawadDepartment of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Ali M Ali Al-NuaimiGilgamesh Ahliya University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a leading cause of mortality among men worldwide, particularly in the USA and European nations, with an estimated 1.9 million new cases and over 580,000 deaths annually, according to recent global statistics. The treatment of prostate tumors presents significant clinical challenges, due to the disease's high metastatic potential, specifically to vital organs, such as the liver, lungs, bones, and brain. The intrinsic heterogeneity of prostate cancer cells, characterized by diverse genetic, molecular, and phenotypic profiles, complicates conventional therapeutic strategies, highlighting the need for advanced diagnostic and treatment modalities. Nanoparticles play a critical role in oncology field due to their unique physicochemical properties, including high surface area-to-volume ratio and the ability to be functionalized with targeting ligands. Metallic-based nanoparticles exhibits significant potential for applications in field of nanomedicine, drug delivery systems, gene silencing methods, radiotherapy enhancement, cancer diagnostics, and targeted therapeutic interventions. Metal nanoparticles have substantially improved the sensitivity and specificity of major imaging modalities and have demonstrated remarkable efficacy as biosensors for the detection of prostate cancer-specific biomarkers. This review article provides an in-depth analysis of the utilization of metal nanomaterials in prostate cancer, focusing on their roles in enhancing therapeutic efficacy, advancing diagnostic precision, and supporting the development of novel treatment strategies.

Indexed as

Metal NanoparticlesProstatic NeoplasmsDrug Delivery SystemsHumansMaleNanomedicineImagingMetal nanoparticleNanoformulationsNanotherapyProstate cancerTheranostics

Identifiers

PMID39987535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.